



## Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

Mar 18, 2025

IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results after the market closes on Monday, March 24, 2025. Oncocyte will host a live Zoom webinar to discuss the company's financial results at 2:00 p.m. PT that same day.

The live webinar to discuss financial results, followed by Q&A, will be accessible via registration at the following link: [Oncocyte Q4 2024 Earnings Webinar](#).

An archived replay will be available after the call concludes on Oncocyte's investor relations website at <https://investors.oncocyte.com>.

### **About Oncocyte**

Oncocyte is a leading diagnostics technology company. The company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft™ is a clinical blood-based solid organ transplantation monitoring test. GraftAssure™ is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO™ is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI™ is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit <https://oncocyte.com/>. For more information about our products, please visit the following web pages:

**VitaGraft Kidney™** - <https://oncocyte.com/vitagraft-kidney/VitaGraft Liver™> -

<https://oncocyte.com/vitagraft-liver/>

**GraftAssure™** - <https://oncocyte.com/graftassure/>

**DetermaIO™** - <https://oncocyte.com/determa-io/DetermaCNI™> -

<https://oncocyte.com/determa-cni/>

**VitaGraft™, GraftAssure™, DetermaIO™, and DetermaCNI™ are trademarks of Oncocyte Corporation.**

### **CONTACT:**

Jeff Ramson

PCG Advisory

(646) 863-6893

[jramson@pcgadvisory.com](mailto:jramson@pcgadvisory.com)

Source: OncoCyte Corporation

